

WISCONSIN STATE
LEGISLATURE
COMMITTEE HEARING
RECORDS

2003-04

(session year)

Assembly

(Assembly, Senate or Joint)

**Committee on
Colleges and
Universities
(AC-CU)**

(Form Updated: 11/20/2008)

COMMITTEE NOTICES ...

➤ Committee Reports ... CR
**

➤ Executive Sessions ... ES
**

➤ Public Hearings ... PH
**

➤ Record of Comm. Proceedings ... RCP
**

**INFORMATION COLLECTED BY COMMITTEE
FOR AND AGAINST PROPOSAL ...**

➤ Appointments ... Appt
**

Name:

➤ Clearinghouse Rules ... CRule
**

➤ Hearing Records ... HR (bills and resolutions)
** **03hr_ab0344_AC-CU_pt03**

➤ Miscellaneous ... Misc
**

**Incidence and Fatality from
Meningococcal Disease
Wisconsin, 1993-2002**

**Bureau of Communicable Diseases
Division of Public Health
Wisconsin Department of Health & Family Services**

Meningococcal Disease

- **Infection of blood or spinal fluid caused specifically by the bacterium *Neisseria meningitidis***

Signs and Symptoms

- Sudden onset of fever
- Intense headache
- Nausea and vomiting may occur
- Stiff neck
- Rash (commonly petechial with pink macules, rarely vesicles)
- Delirium and coma

Incubation and Transmission

- **Incubation period: 2-10 days**
 - **3-4 days common**
- **Humans only reservoir**
- **Droplet transmission**
 - **Nose and throat**
- **High carrier-to-case ratio**
 - **colonization more common than invasive disease**

National Epidemiologic Data

- Incidence stable in US since 1960's
(0.9 - 1.5 cases per 100,000 persons per year)
- 95-97% of cases in US are sporadic
(not-outbreak-associated)
- 2,256 cases reported in US in 2000
- 10-15% case fatality proportion


National Epidemiologic Data

- Incidence peaks in late winter
- Highest incidence in infants
- Serogroups B, C, Y & W-135 associated with most invasive disease in US
- % Y serogroup increased from 2% to 31% since 1991


Case Definition

- Resident of Wisconsin
- Onset of disease from 1/1/93 - 12/30/02
- AND one of the following:
 - Positive isolate of *N. meningitidis* taken from a sterile site
 - Positive antigen test for *N. meningitidis* on CSF
 - Gram negative diplococci on gram stain of CSF

Results: Wisconsin Cases, 1993-2002




WI Cases by Month, 1993-2002



WI Annual Incidence, 1993-2002


- **0.88 cases per 100,000 persons per year**
- **Highest incidence in 1994 (1.04 cases per 100,000 persons)**
- **WI incidence less than national incidence (0.9 - 1.5 per 100,000)**

WI Age-Specific Incidence, 1993-2002




WI Incidence by County, 1998-2002

Annual Incidence*



*Per 100,000 Persons




WI Case Characteristics, 1993-2002 (N=462)

<u>Case Characteristic</u>	<u>Descriptive Result</u>
Fatality	12% Fatality ratio
Sex	48% Female
Median Age	18 Years
College Student	9% College students
Pre-Adult*	16% Pre-adults

*Ages 18-24

Pre-Adult* Cases, 1996-2002



* Ages 18-24


Serogrouping, 1993-2002

- **88% of cases between 1996-2002 were serogrouped (*only 18% from 1993-1995*)**
- **Even proportions of major serogroups:**
 - **B* (32%)** *Not covered by vaccine
 - **C (31%)**
 - **Y (33%)**

WI Meningococcal Fatalities 1993-2002


- **48 deaths from meningococcal disease**
- **~ 5 per year (Range: 3 - 7)**
- **12% case fatality ratio**
- **0.09 fatalities per 100,000 persons per year (<1 per million)**

WI Age-Specific Fatality Rates, 1993-2002




Pre-Adults vs. Other Vaccine-Assessable Age Groups

Incidence*




Fatality Rate*




*Per 100,000 persons per year

Fatality Rates - All Ages, 1993-2002



Causes of Death in Wisconsin, 2001



Cause of Death

Data provided by WI Bureau of Health Information

Fatalities by Serogroup

<u>Serogroup</u>	<u># Fatalities*</u>	<u>Fatality Ratio</u>
B	7	7%
C	19	20%
Y	5	5%
W-135	1	13%
Unknown	16	13%

*N=368, fatality status was unknown for 46 cases

Wisconsin College Students, 1996-2002

- **30 cases (53% were 18-19 years old)**
- **6 fatalities (all \geq age 19):**
 - **<1 per year**
 - **4 serogroup C (none previously vaccinated)**
 - **1 serogroup B**
 - **1 unknown serogroup**

Conclusions

- **Number of WI cases relatively consistent over past decade**
- **Low annual incidence**
 - **<1 case per 100,000**
 - **Below national average**
- **Two seasonal peaks**
 - **Winter/Early Spring**
 - **Early Fall**

Conclusions

- **Children age <2 years have 5-fold incidence than any other age group**
- **Proportion pre-adult & college cases increased in 2002**
- **Most cases equally distributed between 3 major serogroups (B, C, Y)**

Conclusions

- **12% case fatality proportion**
 - similar to national data
 - 6 college student deaths in 7 years
- **Serogroup C was associated with highest case fatality (20%)**
- **Pre-adults had significantly higher risk of fatality compared with others**

Meningococcal Vaccine

- **One quadrivalent polysaccharide vaccine licensed in US (\$55.21 per dose)**
- **Effective against A, C, Y, W-135 serogroups in older children and adults**
- **C component poorly immunogenic (not effective) for children <2 years of age**
- **Not effective against serogroup B**

Meningococcal Vaccine


- **Current ACIP guidelines do not recommend routine vaccination**
 - **Ineffectiveness in children <2 years**
 - **Short duration of protection (3-5 years)**
 - **No protection against B serogroup**

Meningococcal Vaccine - Recommended

- **Vaccine recommended:**
 - **Control of outbreaks due to C serogroups (Y and W135 also)**
 - **Travel to countries where *N. meningitidis* is hyperendemic or epidemic**
 - **Certain high-risk populations (terminal complement component deficiencies or anatomic or functional asplenia)**

Vaccine & College Students

- **MMWR, Volume 49, June 2000 (ACIP rec's)**
- **Vaccination of US college students not cost-effective because of low incidence**
- **ACIP: Providers of medical care for *incoming & current college freshman* should inform them of meningococcal disease and benefits of vaccination (vaccinate if student chooses)**



**Disease Fact Sheet Series:**

Meningococcal Disease

(meningococcal meningitis, meningococemia)

What is meningococcal disease?

Meningococcal (mĕ-ning'gō-kok'āl) disease includes meningococcal meningitis and meningococemia (mĕ-ning'gō-kok-sĕ'mĕ-ă). Meningitis is an inflammation of the meninges (mĕ-nin'-jĕz), the tissues that cover the brain and spinal cord. Meningococcal meningitis is a severe form of meningitis caused by the bacterium *Neisseria meningitidis*. Meningococemia is an infection of the blood with *Neisseria meningitidis*.

What are the symptoms?

The signs and symptoms of meningococcal disease can vary widely. Fever, headache, vomiting, stiff neck and a rash are common signs and symptoms of meningococcal meningitis. People with meningococemia often develop a fever, rash, headache and weakness. A person may have either meningococcal meningitis or meningococemia, or both at the same time.

How soon do the symptoms appear?

The symptoms may develop rapidly, sometimes in a matter of hours, but usually over several days. In some cases, death may occur within hours of the onset of symptoms. The symptoms may appear anytime between 2 and 10 days after *exposure*, usually within 3 to 4 days.

Who gets meningococcal disease?

Most people exposed to *Neisseria meningitidis* do not become seriously ill. Anyone can get meningococcal disease, but it is more common in children and young adults. Compared to other persons their age, college freshmen, especially those who live in dormitories, are at modestly increased risk for meningococcal disease.

How is the bacteria that causes meningococcal disease spread?

The meningococcus bacterium is spread by direct, close contact with respiratory and oral secretions (saliva, sputum or nasal mucus) of an infected person. Close contacts include household members, day care center contacts and anyone directly exposed to the patient's oral or nasal secretions. Many people carry this bacterium in their nose and throat without any signs of illness, while others may develop serious symptoms.

When and for how long is an infected person able to spread the disease?

A person may transmit the disease from the time he/she is first infected until the bacteria are no longer present in discharges from the nose and

throat. The duration varies according to treatment used. Patients should be excluded from school, daycare or the work place until at least 24 hours after therapy was begun and the illness has subsided.

What is the treatment for meningococcal disease?

Penicillin is the drug of choice for meningococcal disease, while third generation cephalosporins are reasonable alternatives.

Should people who have been in contact with a person with a diagnosed case of meningococcal disease be treated?

Only people who have been in close contact need to be considered for preventive treatment. Close contacts include household members, intimate contacts (i.e. kissing), persons performing mouth to mouth resuscitation or endotracheal intubation, day care center contacts, or anyone directly exposed to the patient's oral or nasal secretions. Such people are usually advised to take preventive antibiotics, such as rifampin, ciprofloxacin or ceftriaxone. Casual contact that might occur in a regular classroom, office or factory setting is not usually significant enough to cause concern. Close contacts (family, daycare, nursery school, etc.) should be alerted to watch for early signs of illness, especially fever, and seek treatment promptly.

Is there a vaccine to prevent meningococcal disease?

Presently, there is a vaccine that will protect against four of the serogroups of meningococcus. It is recommended in some outbreak situations or for travel to areas of the world where high rates of the disease are known to occur. College freshman should consider receiving the vaccine to decrease their risk of acquiring the disease.

For more information contact your [Local Public Health Department](#).

[Back to Communicable Disease Fact Sheet Series Index Page](#)


Last Revised: *July 02, 2001*




[Back to top](#) | [About](#) | [Contact](#) | [Disclaimer](#) | [Privacy Notice](#) | [Feedback](#)

Wisconsin Department of Health and Family Services


Reported Meningococcal Disease Cases in College Students, Wisconsin, 1989-2002 (n=32).



Reported Meningococcal Disease by Serogroup in College Students, Wisconsin, 1989-2002 (n=32).



Leading Underlying Causes of Death Among 15-24 Year Old Wisconsin Residents, 1995-97.





National Center for Injury Prevention and Control

[NCIPC Home](#) | [WISQARS Home](#) | [Help](#) | [Contact Us](#)

10 Leading Causes of Death, United States 2000, All Races, Both Sexes

Click any colored box for details. Click on any Age Group for Percentages.

Rank	Age Groups									
	<1	1-4	5-9	10-14	15-19	20-24	25-34	35-44	45-54	55+
1	Congenital Anomalies 5,743	Unintentional Injury 1,826	Unintentional Injury 1,391	Unintentional Injury 1,588	Unintentional Injury 6,755	Unintentional Injury 7,358	Unintentional Injury 11,769	Malignant Neoplasms 16,520	Malignant Neoplasms 48,034	Mal Neop 89
2	Short Gestation 4,397	Congenital Anomalies 495	Malignant Neoplasms 489	Malignant Neoplasms 525	Homicide 1,914	Homicide 3,025	Suicide 4,792	Unintentional Injury 15,413	Heart Disease 35,480	H Dis 63
3	SIDS 2,523	Malignant Neoplasms 420	Congenital Anomalies 198	Suicide 300	Suicide 1,621	Suicide 2,373	Homicide 4,164	Heart Disease 13,181	Unintentional Injury 12,278	Chror Resp Dis 10
4	Maternal Pregnancy Comp. 1,404	Homicide 356	Homicide 140	Homicide 231	Malignant Neoplasms 745	Malignant Neoplasms 968	Malignant Neoplasms 3,916	Suicide 6,562	Liver Disease 6,654	Cer vas 9,
5	Placenta Cord Membranes 1,062	Heart Disease 181	Heart Disease 106	Congenital Anomalies 201	Heart Disease 403	Heart Disease 628	Heart Disease 2,958	HIV 5,919	Cerebro-vascular 6,011	Dia Me 9,
6	Respiratory Distress 999	Influenza & Pneumonia 103	Benign Neoplasms 62	Heart Disease 165	Congenital Anomalies 225	Congenital Anomalies 216	HIV 2,437	Liver Disease 3,371	Suicide 5,437	Unint In 7,
7	Unintentional Injury 881	Septicemia 99	Chronic Low. Respiratory Disease 48	Chronic Low. Respiratory Disease 91	Chronic Low. Respiratory Disease 86	HIV 144	Diabetes Mellitus 623	Homicide 3,219	Diabetes Mellitus 4,954	L Dis 5,
8	Bacterial Sepsis 768	Perinatal Period 79	Influenza & Pneumonia 47	Cerebro-vascular 51	Cerebro-vascular 67	Cerebro-vascular 132	Cerebro-vascular 602	Cerebro-vascular 2,599	HIV 4,142	Nej 3,
9	Circulatory System Disease 663	Benign Neoplasms 53	Septicemia 38	Influenza & Pneumonia 40	Influenza & Pneumonia 65	Influenza & Pneumonia 124	Congenital Anomalies 477	Diabetes Mellitus 1,926	Chronic Low. Respiratory Disease 3,251	Su 2,
10	Intrauterine Hypoxia 630	Chronic Low. Respiratory Disease 51	Two Tied 25	Benign Neoplasms 37	Diabetes Mellitus 48	Diabetes Mellitus 114	Liver Disease 415	Influenza & Pneumonia 1,068	Viral Hepatitis 1,894	Sept 2,

[Download Results in a Spreadsheet \(CSV\) File](#) | [Terms for Causes of Death](#) | [Printer-Friendly Version](#)

[Help with Download](#)

Produced By: Office of Statistics and Programming, National Center for Injury Prevention and Control, CDC

Data Source: National Center for Health Statistics (NCHS) Vital Statistics System.

Why Meningococcal vaccine and not the "flu" vaccine?



10 Leading Causes of Deaths, United States 2000, All Races, Both Sexes Ages: 20-24

Cause of Death	Number of Deaths	Percentage of All Deaths in Age Group
All Deaths	17,744	100.0%
Unintentional Injury	7,358	41.5%
Homicide	3,025	17.0%
Suicide	2,373	13.4%
Malignant Neoplasms	968	5.5%
Heart Disease	628	3.5%
Congenital Anomalies	216	1.2%
HIV	144	0.8%
Cerebrovascular	132	0.7%
Influenza & Pneumonia	124	0.7%
Diabetes Mellitus	114	0.6%
All Others	2,662	15.0%

[Download Results in a Spreadsheet \(CSV\) File](#)

[Help with Download](#)

Produced By: Office of Statistics and Programming, National Center for Injury Prevention and Control
Data Source: National Center for Health Statistics (NCHS) Vital Statistics System.



June 30, 2000 / Vol. 49 / No. RR-7

MMWRTM
MORBIDITY AND MORTALITY
WEEKLY REPORT

*Recommendations
and
Reports*

**Prevention and Control
of Meningococcal Disease**

and

**Meningococcal Disease
and College Students**

**Recommendations of the Advisory Committee
on Immunization Practices (ACIP)**

U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES
Centers for Disease Control and Prevention (CDC)
Atlanta, GA 30333



Contents

Prevention and Control of Meningococcal Disease	1
Introduction	1
Background	1
Meningococcal Polysaccharide Vaccines	2
Recommendations for Use of Meningococcal Vaccine	3
Antimicrobial Chemoprophylaxis	5
Prospects for Improved Meningococcal Vaccines	6
Conclusions	6
References	7
Meningococcal Disease and College Students	11
Introduction	13
Background	13
Meningococcal Disease and College Students	15
Meningococcal Vaccine and College Students	17
Recommendations for Use of Meningococcal Polysaccharide Vaccine in College Students	18
Conclusions	19
References	20

Prevention and Control of Meningococcal Disease

Recommendations of the Advisory Committee on Immunization Practices (ACIP)

Summary

This report summarizes and updates an earlier published statement issued by the Advisory Committee on Immunization Practices concerning the control and prevention of meningococcal disease (MMWR 1997:46[No. RR-5]:1-21) and provides updated recommendations regarding the use of meningococcal vaccine.

INTRODUCTION

Each year, 2,400-3,000 cases of meningococcal disease occur in the United States, resulting in a rate of 0.8-1.3 per 100,000 population (1-3). The case-fatality ratio for meningococcal disease is 10% (2), despite the continued sensitivity of meningococcus to many antibiotics, including penicillin (4). Meningococcal disease also causes substantial morbidity: 11%-19% of survivors have sequelae (e.g., neurologic disability, limb loss, and hearing loss [5,6]). During 1991-1998, the highest rate of meningococcal disease occurred among infants aged <1 year; however, the rate for persons aged 18-23 years was also higher than that for the general population (1.4 per 100,000) (CDC, National Electronic Telecommunications System for Surveillance, unpublished data).

BACKGROUND

In the United States, 95%-97% of cases of meningococcal disease are sporadic; however, since 1991, the frequency of localized outbreaks has increased (7-8). Most of these outbreaks have been caused by serogroup C. However, in the past 3 years, localized outbreaks caused by serogroup Y and B organisms have also been reported (8). The proportion of sporadic meningococcal cases caused by serogroup Y also increased from 2% during 1989-1991 to 30% during 1992-1996 (2,9). The proportion of cases caused by each serogroup varies by age group; more than half of cases among infants aged <1 year are caused by serogroup B, for which no vaccine is licensed or available in the United States (2,10).

Persons who have certain medical conditions are at increased risk for developing meningococcal disease, particularly persons who have deficiencies in the terminal common complement pathway (C3, C5-9) (11). Antecedent viral infection, household crowding, chronic underlying illness, and both active and passive smoking also are associated with increased risk for meningococcal disease (12-19). During outbreaks, bar or nightclub patronage and alcohol use have also been associated with higher risk for disease (20-22). In the United States, blacks and persons of low socioeconomic status have been consistently at higher risk for meningococcal disease (2,3,12,18). However, race and low socioeconomic status are likely risk markers, rather than risk factors, for this disease.

A recent multi-state, case-control study, in which controls were matched to case-patients by age group, revealed that in a multivariable analysis (controlling for sex and education), active and passive smoking, recent respiratory illness, corticosteroid use, new residence, new school, Medicaid insurance, and household crowding were all associated with increased risk for meningococcal disease (13). Income and race were not associated with increased risk. Additional research is needed to identify groups at risk that could benefit from prevention efforts.

MENINGOCOCCAL POLYSACCHARIDE VACCINES

The quadrivalent A, C, Y, W-135 vaccine (Menomune®-A,C,Y,W-135, manufactured by Aventis Pasteur) is the formulation currently available in the United States (23). Each dose consists of 50 µg of the four purified bacterial capsular polysaccharides. Menomune® is available in single-dose and 10-dose vials. (Fifty-dose vials are no longer available.)

Primary Vaccination

For both adults and children, vaccine is administered as a 0.5-ml dose. The vaccine can be administered at the same site. A booster should be given at a different anatomic site. Protective immunity is achieved within 7–10 days of vaccination.

Vaccine Immunogenicity and Efficacy

The immunogenicity and clinical efficacy of the serogroup A and C polysaccharide vaccines have been well established. The serogroup A antibody response in some children as young as 3 months of age, although not as high as that occurring in adults is not achieved until age 4–5 years. The serogroup C component is poorly immunogenic in recipients aged <18–24 months (24,25). The serogroups A and C vaccines have demonstrated estimated clinical efficacies of ≥85% in school-aged children and adults and are useful in controlling outbreaks (26–29). Serogroups Y and W-135 polysaccharides are safe and immunogenic in adults and in children aged >2 years (30–32); although clinical protection has not been documented, vaccination with these polysaccharides induces bactericidal antibody. The antibody responses to each of the four polysaccharides in the quadrivalent vaccine are serogroup-specific and independent. Reduced clinical efficacy has not been demonstrated among persons who have received multiple doses of vaccine. However, recent serologic studies have suggested that multiple doses of serogroup C polysaccharide may cause immunologic tolerance to the group C polysaccharide (33,34).

Duration of Protection

In infants and children aged <5 years, measurable levels of antibodies against the group A and C polysaccharides decrease substantially during the first 3 years following a single dose of vaccine; in healthy adults, antibody levels also decrease, but antibodies are still detectable up to 10 years after vaccine administration (25,35–38). Similarly, although vaccine-induced clinical protection likely persists in school-aged children and adults for at least 3 years, the efficacy of the group A vaccine in children aged <5 years

Does not protect against serogroup B. (approx. 32% of cases in WI 1993-2002)

As with many vaccines there have been recent problems with quality and availability of this vaccine (ie. recalls and shortages).

may decrease markedly within this period. In one study, efficacy declined from >90% to <10% 3 years after vaccination among children who were aged <4 years when vaccinated; efficacy was 67% among children who were ≥ 4 years of age at vaccination (39).

RECOMMENDATIONS FOR USE OF MENINGOCOCCAL VACCINE

Current Advisory Committee on Immunization Practices (ACIP) guidelines (1) suggest that routine vaccination of civilians with the quadrivalent meningococcal polysaccharide vaccine is not recommended because of its relative ineffectiveness in children aged <2 years (the age group with the highest risk for sporadic disease) and because of its relatively short duration of protection. However, the vaccine is recommended for use in control of serogroup C meningococcal outbreaks. An outbreak is defined by the occurrence of three or more confirmed or probable cases of serogroup C meningococcal disease during a period of ≤ 3 months, with a resulting primary attack rate of at least 10 cases per 100,000 population. For calculation of this threshold, population-based rates are used and not age-specific attack rates, as have been calculated for college students. These recommendations are based on experience with serogroup C meningococcal outbreaks, but these principles may be applicable to outbreaks caused by the other vaccine-preventable meningococcal serogroups, including Y, W-135, and A.

College freshmen, particularly those living in dormitories or residence halls, are at modestly increased risk for meningococcal disease compared with persons the same age who are not attending college. Therefore, ACIP has developed recommendations that address educating students and their parents about the risk for disease and about the vaccine so they can make individualized, informed decisions regarding vaccination. (See MMWR Vol. 49, RR-7, which can be referenced in the pages following this report.)

Routine vaccination with the quadrivalent vaccine is also recommended for certain high-risk groups, including persons who have terminal complement component deficiencies and those who have anatomic or functional asplenia. Research, industrial, and clinical laboratory personnel who are exposed routinely to *Neisseria meningitidis* in solutions that may be aerosolized also should be considered for vaccination (1).

Vaccination with the quadrivalent vaccine may benefit travelers to and U.S. citizens residing in countries in which *N. meningitidis* is hyperendemic or epidemic, particularly if contact with the local population will be prolonged. Epidemics of meningococcal disease are recurrent in that part of sub-Saharan Africa known as the "meningitis belt," which extends from Senegal in the West to Ethiopia in the East (40). Epidemics in the meningitis belt usually occur during the dry season (i.e., from December to June); thus, vaccination is recommended for travelers visiting this region during that time. Information concerning geographic areas for which vaccination is recommended can be obtained from international health clinics for travelers, state health departments, and CDC (telephone [404] 332-4559; internet <http://www.cdc.gov/travel/>).

Revaccination

Revaccination may be indicated for persons at high risk for infection (e.g., persons residing in areas in which disease is epidemic), particularly for children who were first vaccinated when they were <4 years of age; such children should be considered for

revaccination after 2–3 years if they remain at high risk. Although the need for revaccination of older children and adults has not been determined, antibody levels rapidly decline over 2–3 years, and if indications still exist for vaccination, revaccination may be considered 3–5 years after receipt of the initial dose (1).

Precautions and Contraindications

Polysaccharide meningococcal vaccines (both A/C and A/C/Y/W-135) have been extensively used in mass vaccination programs as well as in the military and among international travelers. Adverse reactions to polysaccharide meningococcal vaccines are generally mild; the most frequent reaction is pain and redness at the injection site, lasting for 1–2 days. Estimates of the incidence of such local reactions have varied, ranging from 4% to 56% (41,42). Transient fever occurred in up to 5% of vaccinees in some studies and occurs more commonly in infants (24,43).

Severe reactions to polysaccharide meningococcal vaccine are uncommon (24,32,41–48) (R. Ball, U.S. Food and Drug Administration, personal communication). Most studies report the rate of systemic allergic reactions (e.g., urticaria, wheezing, and rash) as 0.0–0.1 per 100,000 vaccine doses (24,48). Anaphylaxis has been documented in <0.1 per 100,000 vaccine doses (23,47). Neurological reactions (e.g., seizures, anesthesias, and paresthesias) are also infrequently observed (42,47).

The Vaccine Adverse Events Reporting System (VAERS) is a passive surveillance system that detects adverse events that are temporally (but not necessarily causally) associated with vaccination, including adverse events that occur in military personnel. During 1991–1998, a total of 4,568,572 doses of polysaccharide meningococcal vaccine were distributed; 222 adverse events were reported for a rate of 49 adverse events per million doses. In 1999, 42 reports of adverse events were received, but the total number of vaccine doses distributed in 1999 is not yet available (R. Ball, U.S. Food and Drug Administration, personal communication). In the United States from July 1990 through October 1999, a total of 264 adverse events (and no deaths) were reported. Of these adverse events, 226 were categorized as “less serious,” with fever, headache, dizziness, and injection-site reactions most commonly reported. Thirty-eight serious adverse events (i.e., those that require hospitalization, are life-threatening, or result in permanent disability) that were temporally associated with vaccination were reported. Serious injection site reactions were reported in eight patients and allergic reactions in three patients. Four cases of Guillain-Barré Syndrome were reported in adults 7–16 days after receiving multiple vaccinations simultaneously, and one case of Guillain-Barré Syndrome was reported in a 9-year-old boy 32 days after receiving meningococcal vaccine alone. An additional seven patients reported serious nervous system abnormalities (e.g., convulsions, paresthesias, diplopia, and optic neuritis); all of these patients received multiple vaccinations simultaneously, making assessment of the role of meningococcal vaccine difficult. Of the 15 miscellaneous adverse events, only three occurred after meningococcal vaccine was administered alone. The minimal number of serious adverse events coupled with the substantial amount of vaccine distributed (>4 million doses) indicate that the vaccine can be considered safe (R. Ball, U.S. Food and Drug Administration, personal communication).

Studies of vaccination during pregnancy have not documented adverse effects among either pregnant women or newborns (49–51). Based on data from studies

involving the use of meningococcal vaccines and other polysaccharide vaccines during pregnancy, altering meningococcal vaccination recommendations during pregnancy is unnecessary.

ANTIMICROBIAL CHEMOPROPHYLAXIS

In the United States, the primary means for prevention of sporadic meningococcal disease is antimicrobial chemoprophylaxis of close contacts of infected persons (Table 1). Close contacts include a) household members, b) day care center contacts, and c) anyone directly exposed to the patient's oral secretions (e.g., through kissing, mouth-to-mouth resuscitation, endotracheal intubation, or endotracheal tube management). The attack rate for household contacts exposed to patients who have sporadic meningococcal disease is an estimated four cases per 1,000 persons exposed, which is 500-800 times greater than for the total population (52). Because the rate of secondary disease for close contacts is highest during the first few days after onset of disease in the index patient, antimicrobial chemoprophylaxis should be administered as soon as possible (ideally within 24 hours after identification of the index patient). Conversely, chemoprophylaxis administered >14 days after onset of illness in the index patient is probably of limited or no value. Oropharyngeal or nasopharyngeal cultures are not helpful in determining the need for chemoprophylaxis and may unnecessarily delay institution of this preventive measure.

Table 1. Schedule for administering chemoprophylaxis for meningococcal disease

Drug	Age group	Dosage	Duration and route of administration
Rifampin*	Children aged <1 month	5 mg/kg every 12 hrs	2 days, orally
	Children aged ≥1 month	10 mg/kg every 12 hrs	2 days, orally
	Adults	600 mg every 12 hrs	2 days, orally
Ciprofloxacin†	Adults	500 mg	Single dose, orally
Ceftriaxone	Children aged <15 years	125 mg	Single dose, IM [§]
Ceftriaxone	Adults	250 mg	Single dose, IM [§]

*Rifampin is not recommended for pregnant women because the drug is teratogenic in laboratory animals. Because the reliability of oral contraceptives may be affected by rifampin therapy, alternative contraceptive measures should be considered while rifampin is being administered.

† Ciprofloxacin is not generally recommended for persons <18 years of age or for pregnant and lactating women because the drug causes cartilage damage in immature laboratory animals. However, ciprofloxacin can be used for chemoprophylaxis of children when no acceptable alternative therapy is available.

§ Intramuscular.

Rifampin, ciprofloxacin, and ceftriaxone are all 90%–95% effective in reducing nasopharyngeal carriage of *N. meningitidis* and are all acceptable alternatives for chemoprophylaxis (53–56). Systemic antimicrobial therapy of meningococcal disease with agents other than ceftriaxone or other third-generation cephalosporins may not reliably eradicate nasopharyngeal carriage of *N. meningitidis*. If other agents have been used for treatment, the index patient should receive chemoprophylactic antibiotics for eradication of nasopharyngeal carriage before being discharged from the hospital (57).

PROSPECTS FOR IMPROVED MENINGOCOCCAL VACCINES

Serogroup A, C, Y, and W-135 meningococcal polysaccharides have been chemically conjugated to protein carriers. These meningococcal conjugate vaccines provoke a T-cell-dependent response that induces a stronger immune response in infants, primes immunologic memory, and leads to booster response to subsequent doses. These vaccines are expected to provide a longer duration of immunity than polysaccharides, even when administered in an infant series, and may provide herd immunity through protection from nasopharyngeal carriage. Clinical trials evaluating these vaccines are ongoing (58–60). When compared with polysaccharide vaccine, conjugated A and C meningococcal vaccines in infants and toddlers have resulted in similar side effects but improved immune response. Prior vaccination with group C polysaccharide likely does not prevent induction of memory by a subsequent dose of conjugate vaccine (61).

In late 1999, conjugate C meningococcal vaccines were introduced in the United Kingdom, where rates of meningococcal disease are approximately 2 per 100,000 population, and 30%–40% of cases are caused by serogroup C (62). In phase I of this program, infants are being vaccinated at 2, 3, and 4 months concurrently with DTP, Hib, and polio vaccines. Children aged 4–13 months are receiving “catch-up” vaccinations. Children aged 15–17 years are receiving one dose of conjugate C vaccine, and entering college students are receiving one dose of bivalent A/C polysaccharide vaccine. In phase II, scheduled to start in June 2000, a dose of conjugate vaccine will be administered to children aged 14 months–14 years and to persons aged 18–20 years who are not enrolled in college (62).

Conjugate meningococcal vaccines should be available in the United States within the next 2–4 years. In the interim, the polysaccharide vaccine should not be incorporated into the routine childhood immunization schedule, because the currently available meningococcal polysaccharide vaccines provide limited efficacy of short duration in young children (39), in whom the risk for disease is highest (2,3).

Because the group B polysaccharide is not immunogenic in humans, immunization strategies have focused primarily on noncapsular antigens (10,63). Several of these vaccines, developed from specific strains of serogroup B meningococci, have been safe, immunogenic, and efficacious among children and adults and have been used to control outbreaks in South America and Scandinavia (64–68). Strain-specific differences in outer-membrane proteins suggest that these vaccines may not provide protection against all serogroup B meningococci (69). No serogroup B vaccine is currently licensed or available in the United States.

CONCLUSIONS

N. meningitidis is a leading cause of bacterial meningitis and sepsis in older children and young adults in the United States. Antimicrobial chemoprophylaxis of close contacts of persons who have sporadic meningococcal disease is the primary means for prevention of meningococcal disease in the United States.

The quadrivalent polysaccharide meningococcal vaccine (which protects against serogroups A, C, Y, and W-135) is recommended for control of serogroup C meningococcal disease outbreaks and for use among persons in certain high-risk groups. Travelers to countries in which disease is hyperendemic or epidemic may benefit from vaccination. In addition, college freshmen, especially those who live in dormitories, should

be educated about meningococcal disease and the vaccine so that they can make an educated decision about vaccination.

Conjugate C meningococcal vaccines were recently introduced into routine childhood immunization schedules in the United Kingdom. These vaccines should be available in the United States within 2–4 years, offering a better tool for control and prevention of meningococcal disease.

References

1. CDC. Control and prevention of meningococcal disease and Control and prevention of serogroup C meningococcal disease: evaluation and management of suspected outbreaks. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1997;46(No. RR-5):1–21.
2. Rosenstein NE, Perkins BA, Stephens DS, et al. The changing epidemiology of meningococcal disease in the United States, 1992–1996. J Infect Dis 1999;180:1894–901.
3. Jackson LA, Wenger JD. Laboratory-based surveillance for meningococcal disease in selected areas, United States, 1989–1991. MMWR 1993;42:21–30.
4. Rosenstein NE, Stocker SA, Popovic T, Tenover F, Perkins B, Active Bacterial Core Surveillance Team. Antimicrobial resistance of *Neisseria meningitidis* in the United States, 1997. Clin Infect Dis 2000;30:212–3.
5. Kirsch EA, Barton RP, Kitcahen L, Giroir BP. Pathophysiology, treatment and outcome of meningococemia: a review and recent experience. Pediatr Infect Dis 1996;15:967–79.
6. Edwards MS, Baker CJ. Complications and sequelae of meningococcal infections in children. J Pediatr 1981;99:540–5.
7. Jackson LA, Schuchat A, Reeves MW, Wenger JD. Serogroup C meningococcal outbreaks in the United States: an emerging threat. JAMA 1995;273:383–9.
8. Woods CR, Rosenstein N, Perkins BA. *Neisseria meningitidis* outbreaks in the United States, 1994–97. In: Abstracts of the 38th Annual Meeting of the Infectious Diseases Society of America, Denver, Colorado, November 12–15, 1998:125FR.
9. CDC. Serogroup Y meningococcal disease—United States, 1989–1996. MMWR 1996;45:1010–3.
10. Fischer M, Perkins BA. *Neisseria meningitidis* Serogroup B: emergence of the ET-5 Complex. Sem Pediatr Infect Dis 1997;8:50–6.
11. Figueroa JE, Densen P. Infectious diseases associated with complement deficiencies. Clin Microbiol Rev 1991;4:359–95.
12. Fischer M, Hedberg K, Cardosi P, et al. Tobacco smoke as a risk factor for meningococcal disease. Pediatr Infect Dis J 1997;16:979–83.
13. Fischer M, Harrison L, Farley M, et al. Risk factors for sporadic meningococcal disease in North America. In: Abstracts of the 38th Annual Meeting of the Infectious Diseases Society of America, Denver, Colorado, November 12–15, 1998:180.
14. Stephens DS, Hajjeh RA, Baughman WS, Harvey RC, Wenger JD, Farley MM. Sporadic meningococcal disease in adults: results of a 5-year population-based study. Ann Intern Med 1995;123:937–9.
15. Cartwright KA, Jones DM, Smith AJ, Stuart JM, Kaczmarek ER, Palmer SR. Influenza A infection and meningococcal disease. Lancet 1991;338:554–7.
16. Moore PS, Hierholzer J, DeWitt W, et al. Respiratory viruses and mycoplasma as cofactors for epidemic group A meningococcal meningitis. JAMA 1990;264:1271–5.
17. Stanwell-Smith RE, Stuart JM, Hughes AO, Robinson P, Griffin MB, Cartwright K. Smoking, the environment and meningococcal disease: a case control study. Epidemiol Infect 1994;112:315–28.
18. Stuart JM, Cartwright KA, Dawson JA, Richard J, Noah ND. Risk factors for meningococcal disease: a case control study in south west England. Community Medicine 1988;10:139–46.
19. Zeitz P, Jafari H, Kioski C, et al. A cluster of *Neisseria meningitidis* serogroup C disease in Phoenix: risk factors for disease. American Society for Microbiology 1993;1388.

20. Imrey PB, Jackson LA, Ludwinski PH, et al. Outbreak of serogroup C meningococcal disease associated with campus bar patronage. *Am J Epidemiol* 1996;143:624-30.
21. Imrey PB, Jackson LA, Ludwinski PH, et al. Meningococcal carriage, alcohol consumption, and campus bar patronage in a serogroup C meningococcal disease outbreak. *J Clin Microbiol* 1995;33:3133-7.
22. Cookson ST, Corrales JL, Lotero JO, et al. Disco fever: epidemic meningococcal disease in Northeastern Argentina associated with disco patronage. *J Infect Dis* 1998;178:266-9.
23. Medical Economics Company. Drug topics red book. Montvale, NJ: Medical Economics Co., Inc., 1995-1999.
24. Peltola H, Kayhty H, Kuronen T, Haque N, Sarna S, Makela PH. Meningococcus group A vaccine in children three months to five years of age: adverse reactions and immunogenicity related to endotoxin content and molecular weight of the polysaccharide. *J Pediatr* 1978;92:818-22.
25. Gold R, Lepow ML, Goldschneider I, Draper TF, Gotschlich EC. Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children. *J Infect Dis* 1979;140:690-7.
26. Rosenstein N, Levine O, Taylor J, et al. Efficacy of meningococcal vaccine and barriers to vaccination. *JAMA* 1998;279:435-9.
27. Pinner RW, Onyango F, Perkins BA, et al. Epidemic meningococcal disease in Nairobi, Kenya, 1989. *J Infect Dis* 1992;166:359-64.
28. Taunay AE, Feldman RA, Bactos CO, Galvao PA, de Moraes JS, Castro IO. Assessment of the protection conferred by anti-group C meningococcal polysaccharide vaccine to 6 to 36 month-old children [Portuguese]. *Rev Inst Adolfo Lutz* 1978;38:77-82.
29. Cochi SL, Markowitz L, Joshi DD, et al. Control of epidemic group A meningococcal meningitis in Nepal. *Int J Epidemiol* 1987;16:91-7.
30. Griffis JM, Brandt BL, Broude DD. Human immune response to various doses of group Y and W135 meningococcal polysaccharide vaccines. *Infect Immun* 1982;37:205-8.
31. Armand J, Arminjon F, Mynard MC, Lefaix C. Tetravalent meningococcal polysaccharide vaccine groups A, C, Y, W135: clinical and serologic evaluation. *J Biol Stand* 1982;10:335-9.
32. Ambrosch F, Wiedermann G, Crooy P, George AM. Immunogenicity and side-effects of a new tetravalent meningococcal polysaccharide vaccine. *Bull World Health Organ* 1983;61:317-9.
33. Granoff DM, Gupta RK, Belshe RB, Anderson EL. Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination. *J Infect Dis* 1998;178:870-4.
34. MacDonald NE, Halperin SA, Law BJ, Forrest B, Danzig LE, Granoff DM. Induction of immunologic memory by conjugates vs. plain meningococcal C polysaccharide vaccine in toddlers. *JAMA* 1998;280:1685-9.
35. Artenstein MS. Meningococcal infections. 5. Duration of polysaccharide-vaccine-induced antibody. *Bull World Health Organ* 1971;45:291-3.
36. Lepow ML, Goldschneider I, Gold R, Randolph M, Gotschlich EC. Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines. *Pediatrics* 1977;60:673-80.
37. Kayhty H, Karanko V, Peltola H, Sarna S, Makela PH. Serum antibodies to capsular polysaccharide vaccine of group A *Neisseria meningitidis* followed for three years in infants and children. *J Infect Dis* 1980;142:861-8.
38. Zangwill KM, Stout RW, Carlone GM, et al. Duration of antibody response after meningococcal polysaccharide vaccination in U.S. Air Force personnel. *J Infect Dis* 1994;169:847-52.
39. Reingold AL, Broome CV, Hightower AW, et al. Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. *Lancet* 1985;2:114-8.
40. Reido FX, Plikaytis BD, Broome CV. Epidemiology and prevention of meningococcal disease. *Pediatr Infect Dis J* 1995;14:643-57.

41. Lepow ML, Beeler J, Randolph M, Samuelson JS, Hankins WA. Reactogenicity and immunogenicity of a quadrivalent combined meningococcal polysaccharide vaccine in children. *J Infect Dis* 1986;154:1033-6.
42. Scheifele DW, Fjornson G, Boraston S. Local adverse effects of meningococcal vaccine. *Can Med Assoc J* 1994;150:14-5.
43. Gold R, Lepow ML, Goldschneider I, Draper TL, Gotschlich EC. Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants. *J Clin Invest* 1975;56:1536-47.
44. Makela PH, Peltola H, Kayhty H, et al. Polysaccharide vaccines of group A *Neisseria meningitidis* and *Haemophilus influenzae* type b: a field trial in Finland. *J Infect Dis* 1977;136 (suppl.):S43-S50.
45. Peltola H, Makela PH, Elo O, Pettay O, Renkonen OV, Sivonen A. Vaccination against meningococcal group A disease in Finland 1974-75. *Scand J Infect Dis* 1976;8:169-74.
46. Hankins WA, Gwaltney JM, Jr., Hendley JO, Farquhar JD, Samuelson JS. Clinical and serological evaluation of a meningococcal polysaccharide vaccine. Groups A, C, Y, and W135. *Proc Soc Exp Biol Med* 1982;169:54-7.
47. Roberts JSC, Bryett KA. Incidence of reactions to meningococcal A & C vaccine among U.K. schoolchildren. *Public Health* 1988;102:471-6.
48. Yergeau A, Alain L, Pless R, Robert Y. Adverse events temporally associated with meningococcal vaccines. *Can Med Assoc J* 1996;154:503-7.
49. de Andrade Carvalho A, Giampaglia CM, Kimura H, et al. Maternal and infant antibody response to meningococcal vaccination in pregnancy. *Lancet* 1977;2:890-11.
50. McCormick JB, Gusmao HH, Nakamura S, et al. Antibody response to serogroup A and C meningococcal polysaccharide vaccines in infants born of mothers vaccinated during pregnancy. *J Clin Invest* 1980;65:1141-4.
51. Leston GW, Little JR, Ottman J, Miller GL. Meningococcal vaccine in pregnancy: an assessment of infant risk. *Pediatr Infect Dis J* 1998;17:261-3.
52. The meningococcal disease surveillance group. Analysis of endemic meningococcal disease by serogroup and evaluation of chemoprophylaxis. *J Infect Dis* 1976;134:201-4.
53. Broome CV. The carrier state: *Neisseria meningitidis*. *J Antimicrob Chemother* 1986;18 (suppl. A):25-34.
54. Gaunt PN, Lambert BE. Single dose ciprofloxacin for the eradication of pharyngeal carriage of *Neisseria meningitidis*. *J Antimicrob Chemother* 1988;21:489-96.
55. Dworzack DL, Sanders CC, Horowitz EA, et al. Evaluation of single-dose ciprofloxacin in the eradication of *Neisseria meningitidis* from nasopharyngeal carriers. *Antimicrob Agents Chemother* 1988;32:1740-1.
56. Schwartz B, Al-Tobaiqi A, Al-Ruwais A, et al. Comparative efficacy of ceftriaxone and rifampin in eradicating pharyngeal carriage of group A *Neisseria meningitidis*. *Lancet* 1988;2:1239-42.
57. Abramson JS, Spika JS. Persistence of *Neisseria meningitidis* in the upper respiratory tract after intravenous antibiotic therapy for systemic meningococcal disease. *J Infect Dis* 1985;151:370-1.
58. Campagne G, Garba A, Fabre P, et al. Safety and immunogenicity of three doses of a *N. meningitidis* A/C diphtheria conjugate vaccine in infants in Niger. *Pediatr Infect Dis J* 2000;19:144-50.
59. Twumasi PA, Kumah S, Leach A. A trial of a group A plus group C meningococcal polysaccharide-protein conjugate vaccine in African infants. *J Infect Dis* 1995;171:632-8.
60. Leach A, Twumasi PA, Kumah S, et al. Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine. *J Infect Dis* 1997;175:200-4.
61. MacLennan J, Obara S, Deeks J, et al. Immune response to revaccination with meningococcal A and C polysaccharides in Gambian children following repeated immunization during early childhood. *Vaccine* 1999;17:3086-93.

62. Public Health Laboratory Service. Vaccination programme for group C meningococcal infection is launched. *CDR Weekly* 1999;9:261-4.
63. Frasch CE. Vaccines for the prevention of meningococcal disease. *Clin Microbiol Rev* 1989;2:S134-S138
64. Bjune G, Hoiby EA, Gronnesby JK, et al. Effect of outer membrane vesicle vaccine against serogroup B meningococcal disease in Norway. *Lancet* 1998;338:1093-6.
65. Sierra GVG, Campo HC, Varcacel NM, et al. Vaccine against group B *Neisseria meningitidis*: protection trial and mass vaccination results in Cuba. *NIPH Ann* 1991;14:195-210.
66. Zollinger WD, Boslego J, Moran E. Meningococcal serogroup B vaccine protein trial and follow-up studies. *NIPH Ann* 1991;14:211-3.
67. de Moraes JC, Perkins BA, Camargo MC, et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. *Lancet* 1992;340:1074-8.
68. Tappero JW, Lagos R, Ballesteros AM, et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. *JAMA* 1999;281:1520-7.
69. Tondella MLC, Rosenstein NE, Williams D, Popovic T, Perkins B, Carlone GM. Distribution of *Neisseria meningitidis* serogroup B serotypes and serosubtypes circulating in the United States: identification of predominant antigens for inclusion in a multivalent outer membrane protein-based vaccine. In: Abstracts of the 99th General Meeting of the American Society of Microbiology, Chicago, IL, May 30-June 3, 1999:D/B9.

Meningococcal Disease and College Students

**Recommendations of the Advisory Committee
on Immunization Practices (ACIP)**

Meningococcal Disease and College Students

Recommendations of the Advisory Committee on Immunization Practices (ACIP)

Summary

This report provides information regarding the modestly increased risk for meningococcal disease among college freshmen, particularly those who live in dormitories or residence halls. It presents recommendations developed by the Advisory Committee on Immunization Practices regarding the education of students and parents about meningococcal disease and the polysaccharide meningococcal vaccine so that they can make informed decisions regarding vaccination.

INTRODUCTION

Neisseria meningitidis causes both sporadic disease and outbreaks. As a result of the control of *Haemophilus influenzae* type b infections, *N. meningitidis* has become the leading cause of bacterial meningitis in children and young adults in the United States (1). Outbreaks of meningococcal disease were rare in the United States in the 1980s; however, since 1991, the frequency of localized outbreaks has increased (2). From July 1994 through July 1997, 42 meningococcal outbreaks were reported, four of which occurred at colleges (3). However, outbreaks continue to represent <3% of total U.S. cases (3).

Rates of meningococcal disease remain highest for infants, but in the past decade, rates have increased among adolescents and young adults (4). During 1994–1998, approximately two thirds of cases among persons aged 18–23 years were caused by serogroups C, Y, or W135 and therefore were potentially preventable with available vaccines (5) (CDC, unpublished data) (Figure 1). Although the quadrivalent meningococcal polysaccharide vaccine is safe and efficacious (5,6), decisions about who to target for vaccination require understanding of the groups at risk, the burden of disease, and the potential benefits of vaccination.

New data are available regarding the risk for meningococcal disease in college students. This report reviews these data and provides medical professionals with guidelines concerning meningococcal disease and college students.

BACKGROUND


Meningococcal Disease in the Military

Military recruits and college freshmen have several common characteristics (e.g., age, diverse geographic backgrounds, and crowded living conditions). Therefore, data obtained from recruits have been used to evaluate meningococcal disease and vaccine among college freshmen.

Before 1971, rates of meningococcal disease were elevated among U.S. military recruits. Outbreaks frequently followed large-scale mobilizations, and recruits in their

FIGURE 1. Serogroup distribution of meningococcal disease cases, by age group—United States, 1994–1998

Number of cases



initial training camps were at substantially greater risk for disease than were regular troops (7). Military recruits enter military service for the first time at a few large U.S. military recruit training centers. After 8–12 weeks of initial training, they disperse to perform their military service at many different locations. During mobilization for the Vietnam conflict, outbreaks of meningococcal disease at training camps involving substantial numbers of recruits were caused by sulfadiazine-resistant strains of *N. meningitidis*. During 1964–1970, the rate of hospitalizations resulting from meningococcal disease among all active duty service members was 25.2 per 100,000 person-years (LTC Frederick Erdtmann, MD, MPH, Office of the Surgeon General, U.S. Army, briefing, 1981). These circumstances led to development of meningococcal polysaccharide vaccines (8). Field trials of group C polysaccharide vaccine among U.S. Army recruits demonstrated an 89.5% reduction in the rate of serogroup C meningococcal disease among vaccinated versus nonvaccinated recruits (9,10); thus, beginning in October 1971, all new recruits were vaccinated with the group C vaccine (11), and by Fall 1982, all recruits were receiving the quadrivalent polysaccharide vaccine (7). However, rates of meningococcal disease in U.S. Army personnel declined before the 1971 vaccination campaigns (7), suggesting that smaller recruit populations at training installations and the natural periodicity of outbreaks may have contributed to the decline in disease.

Rates of meningococcal disease remain low in the military, and large outbreaks no longer occur. Since 1990, records of all hospitalizations of active duty service members in military hospitals worldwide have been integrated with military personnel records in the Defense Medical Surveillance System (DMSS). During 1990–1998, the overall rate of hospitalizations from meningococcal disease among enlisted, active-duty service members was 0.51 per 100,000 person-years (J. Brundage, DMSS Army Medical Surveillance Activity, personal communication).

Approximately 180,000 military recruits receive a single dose of quadrivalent polysaccharide meningococcal vaccine annually. Revaccination is only indicated when military personnel are traveling to countries in which *N. meningitidis* is hyperendemic or epidemic (D. Trump, personal communication).

Before 1999, students reporting to two of the U.S. military academies routinely received meningococcal vaccine. Last year, the other academies initiated meningococcal vaccine programs.

MENINGOCOCCAL DISEASE AND COLLEGE STUDENTS

Four recent studies provide data concerning the risk for sporadic meningococcal disease among college students (Table 1) (12–15). The earliest of these studies was conducted during the 1990–1991 and 1991–1992 school years. A questionnaire designed to evaluate risk factors for meningococcal disease among college students was sent to 1,900 universities, resulting in a 38% response rate (12). Forty-three cases of meningococcal disease were reported during the 2 years from colleges with a total enrollment of 4,393,744 students, for a low overall incidence of 1.0 per 100,000 population per year. However, cases of meningococcal disease occurred 9–23 times more frequently in students residing in dormitories than in those residing in other types of accommodations. The low response rate and the inability of the study to control for other risk factors (e.g., freshman status) make these results difficult to interpret.

Table 1. Studies of the risk for meningococcal disease among college students

	Study A*	Study B [†]	Study C [‡]	Study D [§]	Study E [¶]
Are college students at higher risk than the general population of similar age?	no	no	no	N/A	yes
Among college students, are freshmen at higher risk?	N/A	no	yes	no	N/A
Among college students, are students living in dormitories/catered halls at higher risk?	yes	yes	yes	no	yes
Among college students, are freshmen living in dormitories at higher risk?	N/A	N/A	yes	yes	N/A

* Froeschle J. Meningococcal disease in college students. *Clin Infect Dis* 1999;29:215–6.

[†] Harrison LH, Dwyer DM, Maples CT, Billmann L. Risk of meningococcal infection in college students. *JAMA* 1999;281:1906–10.

[‡] Bruce M, Rosenstein NE, Capparella J, Perkins BA, Collins MJ. Meningococcal disease in college students. In: Abstracts of the 39th Annual Meeting of the Infectious Diseases Society of America, Philadelphia, PA, November 18–21, 1999:63.

[¶] Neal KR, Nguyen-Van-Tam J, Monk P, O'Brien SJ, Stuart J, Ramsay M. Invasive meningococcal disease among university undergraduates: association with universities providing relatively large amounts of catered hall accommodations. *Epidemiol Infect* 1999;122:351–7.

N/A= not applicable.

In a retrospective, cohort study conducted in Maryland for the period 1992–1997, 67 cases of meningococcal disease among persons aged 16–30 years were identified by active, laboratory-based surveillance (13). Of those cases, 14 were among students attending Maryland colleges, and 11 were among those in 4-year colleges. The overall incidence of meningococcal disease in Maryland college students was similar to the incidence in the U.S. population of persons the same age (1.74/100,000 vs. 1.44/100,000, respectively); however, rates of disease were elevated among students living in dormitories compared with students living off-campus (3.2/100,000 vs. 0.96/100,000, $p=0.05$).

U.S. surveillance for meningococcal disease in college students was initiated in 1998; from September 1998 through August 1999, 90 cases of meningococcal disease were reported to CDC (14). These cases represent approximately 3% of the total cases of meningococcal disease that occur each year in the United States. Eighty-seven (97%) cases occurred in undergraduate students, and 40 (44%) occurred among the 2.27 million freshman students entering college each year (16). Among undergraduates, of the 71 (82%) isolates for which serogroup information was available, 35 (49%) were serogroup C, 17 (24%) were serogroup B, 15 (21%) were serogroup Y, and one (1%) was serogroup W-135. Eight (9%) students died. Of the five students who died for whom serogroup information was available, four had serogroup C isolates and one had serogroup Y.

U.S. surveillance data from the 1998–1999 school year suggest that the overall rate of meningococcal disease among undergraduate college students is lower than the rate among persons aged 18–23 years who are not enrolled in college (Table 2) (0.7 vs. 1.5/100,000, respectively) (14,16). However, rates were higher among specific subgroups of college students. Among the approximately 590,000 freshmen who live in dormitories (17), the rate of meningococcal disease was 4.6/100,000, higher than any age group in the population other than children aged <2 years, but lower than the threshold of 10/100,000 recommended for initiating meningococcal vaccination campaigns (6).

Of 90 students who had meningococcal disease attending college during the 1998–

Table 2. Rates of meningococcal disease, by risk group—United States, September 1998–August 1999*

Risk group	Number of cases	Population	Rate per 100,000
Children aged 2–5 years	255	14,886,569 [†]	1.7
Persons aged 18–23 years	304	22,070,535 [†]	1.4
Non-college students aged 18–23 years	216	14,579,322 ^{‡§}	1.5
College students	90	14,897,268 [§]	0.6
Undergraduates	87	12,771,228 [§]	0.7
Freshmen [¶]	40	2,285,001 [§]	1.8
Dormitory residents	45	2,085,618 ^{§**}	2.2
Freshmen [¶] living in dormitories	27	591,587 ^{§**}	4.6

* Bruce M, Rosenstein NE, Capparella J, Perkins BA, Collins MJ. Meningococcal disease in college students. In: Abstracts of the 39th Annual Meeting of the Infectious Diseases Society of America, Philadelphia, PA, November 18–21, 1999:63.

[†] 1998 census data.

[§] NCES, U.S. Dept of Education, 1996–1997.

[¶] Students enrolled in any postsecondary education for the first time.

** National College Health Risk Behavior Survey (NCHRBS)—United States, 1995.

1999 school year, 50 were enrolled in a case-control study and matched to 148 controls by school, sex, and undergraduate vs. graduate status (14). In a multivariable analysis, freshmen living in dormitories were at higher risk for meningococcal disease. In addition, white race, radiator heat, and recent upper respiratory infection were associated with disease.

In contrast to the United States, overall rates of meningococcal disease in the United Kingdom are higher among university students compared with non-students of similar age (15). From September 1994 through March 1997, university students had an increased annual rate of meningococcal disease (13.2/100,000) compared with non-students of similar age in the same health districts (5.5/100,000) and in those health districts without universities (3.7/100,000). As in the United States, regression analysis revealed that "catered hall accommodations," the U.K. equivalent of dormitories, were the main risk factor. Higher rates of disease were observed at universities providing catered hall accommodations for >10% of their student population compared with those providing such housing for <10% of students (15.3/100,000 vs. 5.9/100,000). The increased rate of disease among university students has prompted the United Kingdom to initiate routine vaccination of incoming university students with a bivalent A/C polysaccharide vaccine as part of a new vaccination program (see *MMWR* 2000; Vol.49, No. RR-6 which can be referenced in the pages preceding this report) (18).

MENINGOCOCCAL VACCINE AND COLLEGE STUDENTS

On September 30, 1997, the American College Health Association (ACHA), which represents about half of colleges that have student health services, released a statement recommending that "college health services [take] a more proactive role in alerting students and their parents about the dangers of meningococcal disease," that "college students consider vaccination against potentially fatal meningococcal disease," and that "colleges and universities ensure all students have access to a vaccination program for those who want to be vaccinated" (Dr. MarJeanne Collins, Chairman, ACHA Vaccine Preventable Diseases Task Force, personal communication). Parent and college student advocates have also encouraged more widespread use of meningococcal vaccine in college students. In a joint study by ACHA and CDC, surveys were sent to 1,200 ACHA-member schools; of 691 responding schools, 57 (8%) reported that pre-exposure meningococcal vaccination campaigns had been conducted on their campus since September 1997. A median of 32 students were vaccinated at each school (range: 1-2,300) (J. Capparella, unpublished data). During the 1998-1999 school year, 3%-5% of 148 students enrolled in a case-control study reported receiving prophylactic meningococcal vaccination (14). Before the 1999 fall semester, many schools mailed information packets to incoming freshmen; data are not yet available regarding the proportion of students who have been vaccinated.

Cost-effectiveness of meningococcal vaccine in college students

From a societal perspective, the economic costs and benefits of vaccinating a) a cohort of 591,587 freshmen who live in dormitories and b) all freshman enrolled in U.S. colleges, regardless of housing status (n=2.4 million) were evaluated, assuming the benefits of vaccination would last 4 years (Scott et al, unpublished data). Best and

worst case scenarios were evaluated by varying cost of vaccine and administration (range: \$54–\$88), costs per hospitalization (\$10,924–\$24,030), value of premature death based on lifetime productivity (\$1.3–\$4.8 million), cost of side effects of vaccine per case (\$3,500–\$12,270 per one million doses), and average cost of treating a case of sequelae (\$0–\$1,476). Vaccination coverage (60% and 100%) and vaccine efficacy (80% and 90%) were also varied for evaluation purposes.

Vaccination of freshmen who live in dormitories would result in the administration of approximately 300,000–500,000 doses of vaccine each year, preventing 15–30 cases of meningococcal disease and one to three deaths each year. The cost per case prevented would be \$600,000–\$1.8 million, at a cost per death prevented of \$7 million to \$20 million.

Vaccination of all freshman would result in the administration of approximately 1.4–2.3 million doses of vaccine each year, preventing 37–69 cases of meningococcal disease and two to four deaths caused by meningococcal disease each year. The cost per case prevented would be \$1.4–2.9 million, at a cost per death prevented of \$22 million to \$48 million.

These data are similar to data derived from previous studies (19). They suggest that for society as a whole, vaccination of college students is unlikely to be cost-effective (Scott et al, unpublished data).

RECOMMENDATIONS FOR USE OF MENINGOCOCCAL POLYSACCHARIDE VACCINE IN COLLEGE STUDENTS

College freshmen, particularly those who live in dormitories, are at modestly increased risk for meningococcal disease relative to other persons their age. Vaccination with the currently available quadrivalent meningococcal polysaccharide vaccine will decrease the risk for meningococcal disease among such persons. Vaccination does not eliminate risk because a) the vaccine confers no protection against serogroup B disease and b) although the vaccine is highly effective against serogroups C, Y, W-135, and A, efficacy is <100%.

The risk for meningococcal disease among college students is low; therefore, vaccination of all college students, all freshmen, or only freshmen who live in dormitories or residence halls is not likely to be cost-effective for society as a whole. Thus, ACIP is issuing the following recommendations regarding the use of meningococcal polysaccharide vaccines for college students.

- Providers of medical care to incoming and current college freshmen, particularly those who plan to or already live in dormitories and residence halls, should, during routine medical care, inform these students and their parents about meningococcal disease and the benefits of vaccination. ACIP does not recommend that the level of increased risk among freshmen warrants any specific changes in living situations for freshmen.
- College freshmen who want to reduce their risk for meningococcal disease should either be administered vaccine (by a doctor's office or student health service) or directed to a site where vaccine is available.

- The risk for meningococcal disease among non-freshmen college students is similar to that for the general population. However, the vaccine is safe and efficacious and therefore can be provided to non-freshmen undergraduates who want to reduce their risk for meningococcal disease.
- Colleges should inform incoming and/or current freshmen, particularly those who plan to live or already live in dormitories or residence halls, about meningococcal disease and the availability of a safe and effective vaccine.
- Public health agencies should provide colleges and health-care providers with information about meningococcal disease and the vaccine as well as information regarding how to obtain vaccine.

Additional Considerations about Vaccination of College Students

Although the need for revaccination of older children has not been determined, antibody levels decline rapidly over 2–3 years (6). Revaccination may be considered for freshmen who were vaccinated more than 3–5 years earlier (5). Routine revaccination of college students who were vaccinated as freshmen is not indicated.

College students who are at higher risk for meningococcal disease because of a) underlying immune deficiencies or b) travel to countries in which *N. meningitidis* is hyperendemic or epidemic (i.e., the meningitis belt of sub-Saharan Africa) should be vaccinated (6). College students who are employed as research, industrial, and clinical laboratory personnel who are routinely exposed to *N. meningitidis* in solutions that may be aerosolized should be considered for vaccination (6).

No data are available regarding whether other closed civilian populations with characteristics similar to college freshman living in dormitories (e.g., preparatory school students) are at the same increased risk for disease. Prevention efforts should focus on groups in whom higher risk has been documented.


CONCLUSIONS

College freshmen, especially those who live in dormitories, are at a modestly increased risk for meningococcal disease compared with other persons of the same age, and vaccination with the currently available quadrivalent meningococcal polysaccharide vaccine will decrease their risk for meningococcal disease. Continued surveillance is necessary to evaluate the impact of these recommendations, which have already prompted many universities and clinicians to offer vaccine to college freshmen.

Consultation on the use of these recommendations or other issues regarding meningococcal disease is available from the Meningitis and Special Pathogens Branch, Division of Bacterial and Mycotic Diseases, National Center for Infectious Diseases, CDC (telephone: [404] 639-3158).

Acknowledgement

The following persons are acknowledged for their contributions to the economics section of this report: Martin I. Meltzer, Ph.D. and R. Douglas Scott, II, Ph.D.



Menigitis Bill

Kreibich,
GARD, Jensen Hvebsch
Gronemus - Schneider

LRB 1130/2

Fri, MAY 16

Reps

Sen Schultz

Jensen

Leskewitz

Pettis

Ward

~~Ward~~

Wasserman

McCormick

Freeze

OTT

Seratti

Gard

SCHNEIDER

GRONEMUS

Hvebsch

Silling

Buder

Lothian

HaHN

Gottlieb

Sulow

Olson

Bies

Fitzgerald
Bresko